AvenCell Therapeutics, Inc
General information
AvenCell Therapeutics, Inc
500 Forge Road
02472 Watertown, Massachusetts
USA
Contact person: Andrew Schiermeier, Chief Executive Officer
Company main phone: +1 (617) 9417468
Website: https://avencell.com
500 Forge Road
02472 Watertown, Massachusetts
USA
Contact person: Andrew Schiermeier, Chief Executive Officer
Company main phone: +1 (617) 9417468
Website: https://avencell.com
| Year founded: | 2021 |
| Source of foundation: | Independent foundation |
Corporate description / mission:
AvenCell Therapeutics, Inc., a clinical-stage cell therapy company focused on advancing both switchable and allogeneic engineered CAR-T cell therapies. The company builds transformative cell therapy that targets difficult-to-treat cancers, with its lead programs focusing on acute myeloid leukemia (AML) and prostate cancer, and additional programs targeting other hematological malignancies and solid tumors.
AvenCell Therapeutics, Inc., a clinical-stage cell therapy company focused on advancing both switchable and allogeneic engineered CAR-T cell therapies. The company builds transformative cell therapy that targets difficult-to-treat cancers, with its lead programs focusing on acute myeloid leukemia (AML) and prostate cancer, and additional programs targeting other hematological malignancies and solid tumors.
State of ownership: Private / independent
Headquarters: HQ: Yes
Headquarters: HQ: Yes
Categorization
| Sector: |
|
| Subsector: |
|
| Primary therapeutic areas: |
|
| Business model: |
|
| Customer segments: |
|
Summary Products / Services / Technologies
Number of Biotech Products
| Pre-clinical: | 3 | |
| Phase II: | 2 |
Description of products:
AVC-201
AVC-202
AVC-203 etc.
AVC-201
AVC-202
AVC-203 etc.
Technology used:
UniCAR, RevCAR and TCE
UniCAR, RevCAR and TCE
Collaborations & Clients
Partnering strategy / collaborations:
Intellia Therapeutics
Blackstone Lifesciences
Intellia Therapeutics
Blackstone Lifesciences
© 2025 Biotechgate by Venture Valuation